Margaret Dugan Biography and Net Worth

Director of BeOne Medicines

Margaret Dugan, M.D., joined our Board of Directors in February 2022. Dr. Dugan has served as chair of the Compensation Committee since September 2022.

Dr. Dugan has served as Chief Medical Officer of Dracen Pharmaceuticals since 2018. Prior to that, she was Senior Vice President at Novartis Oncology, responsible for global strategic drug development and portfolio management, including translational science, early- and late-stage clinical development, life cycle management and companion diagnostic development that resulted in several regulatory submissions and approvals. For five years, Dr. Dugan led the Novartis Exploratory Oncology Development Group, which transitioned compounds from discovery to proof-of-concept in the clinic. She held several development positions at Schering-Plough (now Merck & Co.) and American Cyanamid (now Pfizer).

Dr. Dugan earned a B.A. and M.D. from New York University and completed training there in hematology and oncology.

What is Margaret Dugan's net worth?: The estimated net worth of Margaret Dugan is at least $7.17 million as of October 16th, 2025. Dr. Dugan owns 24,574 shares of BeOne Medicines stock worth more than $7,172,413 as of May 28th. This net worth approximation does not reflect any other assets that Dr. Dugan may own. Learn More about Margaret Dugan's net worth.
How do I contact Margaret Dugan?: The corporate mailing address for Dr. Dugan and other BeOne Medicines executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. BeOne Medicines can also be reached via phone at 13459494123 and via email at [email protected]. Learn More on Margaret Dugan's contact information.
Has Margaret Dugan been buying or selling shares of BeOne Medicines?: Within the last three months, Margaret Dugan has sold $65,635.20 in shares of BeOne Medicines stock. Most recently, Margaret Dugan sold 212 shares of the business's stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.60, for a transaction totalling $65,635.20. Learn More on Margaret Dugan's trading history.
Who are BeOne Medicines' active insiders?: BeOne Medicines' insider roster includes Margaret Dugan (Director), Chan Lee (SVP), John Oyler (CEO), Alessandro Riva (Director), Aaron Rosenberg (CFO), Corsee Sanders (Director), Corsee Sanders (Director), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeOne Medicines' active insiders.
Are insiders buying or selling shares of BeOne Medicines?: In the last twelve months, insiders at the sold shares 49 times. They sold a total of 391,908 shares worth more than $118,557,647.60. The most recent insider tranaction occured on May, 22nd when Director Alessandro Riva sold 212 shares worth more than $65,616.12. Insiders at BeOne Medicines own 6.2% of the company. Learn More about insider trades at BeOne Medicines.
Information on this page was last updated on 5/22/2026.

Margaret Dugan Insider Trading History at BeOne Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/22/2026	Sell	212	$309.60	$65,635.20

Margaret Dugan Buying and Selling Activity at BeOne Medicines

BeOne Medicines Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Today's Range

Now: $294.27

$288.34

$298.01

50 Day Range

MA: $301.85

$274.73

$323.87

2 Week Range

Now: $294.27

$239.25

$385.22

Volume

166,602 shs

Average Volume

251,503 shs

Market Capitalization

$32.29 billion

P/E Ratio

65.83

Dividend Yield

N/A

Beta

0.5